SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity
- 5 March 2021
- journal article
- review article
- Published by Elsevier BV in Respiratory Medicine
- Vol. 180, 106355
- https://doi.org/10.1016/j.rmed.2021.106355
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human PrimatesACS Infectious Diseases, 2016
- Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell ResponseJournal of Virology, 2015
- Immunosenescence: influenza vaccination and the elderlyCurrent Opinion in Immunology, 2014
- Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoVThe Journal of Immunology, 2008
- Development of subunit vaccines against severe acute respiratory syndromeDrugs of Today, 2008
- A global perspective on vaccine safetyVaccine, 2004
- Effects of a SARS-associated coronavirus vaccine in monkeysThe Lancet, 2003
- A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measlesNature Medicine, 2003
- ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTIONThe Lancet, 1988
- Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in InfantsThe American Journal of Tropical Medicine and Hygiene, 1988